INTRODUCTION
Schizophrenia, which affects approximately 1% of the population, is a devastating illness with a chronic impact on social, vocational, and daily living functioning. 1, 2) Although development of atypical antipsychotics (AAP) has resulted in an important advance in the treatment of schizophrenia, many patients treated with these AAPs still frequently experience lack of efficacy and bothersome side-effects (SEs). 3, 4) In addition, despite numerous AAPs available, the question of which antipsychotic drug should be preferred is still controversial. Nevertheless, switching from one AAP to another with a different SE profile has become a common, and in fact a recommended, strategy aimed at improving clinical outcomes by increasing efficacy and minimizing the SEs of the antipsychotics. 5, 6) In order to do so, understanding the possible benefits and risks associated with switching between AAPs is critical when making an optimum decision. 7) Studies showed that patients with schizophrenia have higher risk of having medical morbidity and mortality risks than general population, 8) and weight gain, in association with metabolic syndromes, has continuously reported to be an important contributing factor to this higher morbidity and mortality of schizophrenia. 9) Recent studies repeatedly showed concerns metabolic SE profiles of AAPs, [10] [11] [12] [13] henceby metabolic profile including weight gain became one of the most important reasons for switching AAP from one to another. [14] [15] [16] Amisulpride has a very selective and high affinity for dopamine (D3/D2) receptors. Amisulpride increases dopaminergic transmission at low doses via presynaptic receptor blockade and blocks dopaminergic transmission at higher dosage. 17) Researches have shown that amisulpride is either more effective or equally effective relative to conventional antipsychotics with respect to positive symptoms for schizophrenia. 18, 19) It also showed superior efficacy than to placebo and conventional antipsychotics with respect to negative symptoms. 20, 21) It has no affinity for other receptor or transporter systems, it is therefore believed to have a lower risk of causing SEs. 22) Studies further showed that amisulpride is associated with significantly less weight gain than other AAPs, and it does not increase body mass index as well as lipid profiles. 23, 24) More importantly, a meta-analysis comparing efficacy and tolerability of 15 antipsychotics (13 AAPs and 2 typical antipsychotics) showed that amisulpride showed the lowest all-cause discontinuation rates and risk of causing sedation. 25) These characteristics suggested that amisulpride may be an alternative option in patients requiring a change in antipsychotic treatment due to lack of efficacy or SEs.
Evidence from both randomized clinical trials (RCTs) and naturalistic trials in routine practice settings is valuable and required in investigating effective pharmacological choices for patients having schizophrenia. 26) RCTs may provide the strongest empirical support, but their biases in patient selection can limit generalizability. 27) Blinded use of placebos also poses ethical controversy. 28) Thus, the purpose of this study was to investigate effect of switching to amisulpride in patients who showed suboptimal effect and/or tolerability to current oral AAP in a naturalistic setting.
METHODS

Study Design
This was a 6-week, prospective, multicenter, open-label, flexible-dose study conducted in three centers in Korea (The Catholic University of Korea, Dongguk University, and Korea University). The study consisted of a switching phase (day 0) and an evaluation phase (week 6). Switching was achieved using cross-titration, with amisulpride in the evening at 300 mg on day 1 then flexibly dosed 400-800 mg/day. Previous antipsychotic medication was tapered to 50% within first 3 days then stopped before day 7. The study was conducted in accordance with Declaration of Helsinki and Good Clinical Practices. All participants provided written consent before participating in this study. The study's protocol was approved by institutional review board of the each study sites. Concomitant ongoing medications including benzodiazepines, zolpidem, anticholinergic, and beta blockers were permitted. However, antidepressants, mood stabilizers, psychoactive medications, and antipsychotics other than amisulpride were not permitted during the study.
Subjects
The present study enrolled Korean outpatients suffering from schizophrenia. The inclusion criteria were as follows: (1) (4) inadequate effect and/or tolerability to current AAP based on clinical response and tolerability. Patients were excluded for any of the following: (1) medication-naive first-episode schizophrenia patients; (2) clinically significant comorbid mental disorders in acute conditions (less than 3 months of symptom stabilization); (3) history of organic mental or neurological disorder, or mental retardation; (4) comorbid substance (alcohol, amphetamine, and opioid) abuse or dependence in acute conditions (less than 3 months of meeting remission criteria); (5) being treated with clozapine; (6) past history of treatment-resistance; (7) having risk of harming self or others; and (8) past history of treatment incompliance.
Measures
Clinical benefit was evaluated using the Clinical Global Impressions-Clinical Benefit (CGI-CB) at baseline and week 6. The CGI-CB, based on the principles outlined in Clinical Global Impression (CGI) item 3 (Efficacy Index), 29) can assess both clinical efficacy and tolerability ( Table 1 ). The scale ranges from 1 to 10 with score of 1 indicating most benefit and 10 indicating no benefit from the treatment. CGI-Severity (CGI-S) scale was used to assess the severity of patients' clinical condition.
The primary end-point measure was proportion of patients achieving improvement in clinical benefit at week 6 based on CGI-CB score. Improvement in clinical benefit was defined as a decrease (＞1 score) from baseline in CGI-CB at week 6. Secondary endpoints were change in CGI-CB, Clinical Global Impressions-Clinical Benefit. The scale ranges from 1 to 10 with score of 1 indicating most benefit and 10 indicating no benefit from the treatment, for instance, CGI-CB points of 4 or less indicate that the patient has clinical benefit rather than side effect, while 5-9 and 10 suggests some or no clinical benefit due to harmful adverse events, respectively. 
Statistical Analysis
For the analysis of all efficacy and safety measures, the intention-to-treat (ITT) population/safety population was used. Thus, patients who received at least one dose of the study medication were included using last-observationcarried-forward (LOCF) method. Kolmogorov-Smiov test was used for verification of regular distribution of data. Student's t-tests were used for the analysis of quantitative variables, and chi-square test or Fisher's exact tests were used for categorical variables. All statistical analyses were conducted using the NCSS 2007 Power Analysis & Sample Size software (NCSS, Kaysville, UT, USA) with a two-tailed significance level of p＜0.05.
RESULTS
Patients and Medications
The baseline demographic and clinical characteristics of the 37 patients are provided in Tables 2 and 3 . Slightly more females (n=21) than males (n=16) were recruited with mean age of 40.68±10.07 years. Majority of them For instant understanding of the figure, when looking at the CGI-CB 1-4 points, 0%, 2.7%, 24.3% and 13.5% of patients' CGI-CB points have changed to CGI-CB points of 1-4 after switching to amisulpride, while none had such points before switching to amisulpride, indicating that switching to amisulpride accounts for more clinical benefit rather than adverse events.
were taking benzodiazepines. Ongoing antipsychotics before switching to amisulpride, were olanzapine, aripiprazole, palipeiridone, blonaserin, and risperidone. All patients were experiencing more than 1 SE. The most common SEs were weight gain, decreased attention, and memory impairment. In average, patients were moderately ill at baseline (CGI-S, 4.17±0.74).
Effectiveness
The proportion of patients showing improvement in terms of clinical benefit as measured by the CGI-CB score at week 6 was 56.8% (21/37; 95% confidence intervals (CIs), 0.3949 to 0.729). The mean dose of amisulpride prescribed was 416.22 mg/day (±230.35). Changes in the frequency of each CGI-CB score at baseline and week 6 are presented in Figure 1 . The most frequent score at baseline on CGI-CB was 7 (29.7%) followed by 8 (27.0%) indicating that the previous antipsychotics that patients were taking resulted in low treatment effect with clinically significant SEs. However, 21.6% of patients had score of 6 indicating treatment effect with some burden of SEs. After 6 weeks of treatment, the most frequent CGI-CB score became 3 (24.3%), and score of 4 increased from 0% to 13.5% indicating favorable treatment outcome after changing to amisulpride. However, the rates of 6 and 7 were also high (for both 18.9%) suggesting that significant number of patients still experienced either low treatment effect or mild treatment effect with some SE burden even after switching to amisulpride.
After changing to amisulpride, CGI-CB and CGI-S showed significant improvement at week 6 compared to baseline (mean changes of CGI-CB and CGI-S: −1.7±1.0, p ＜0.0001 and −0.6±0.0, p=0.001, respectively). However, no symptom improvement was noted in BARS. SSS also improved significantly (mean change: 2.1±2.6, p＜0.0001) ( Table 4) .
Tolerability
Amisulpride therapy was well tolerated, and 75.7% (28/37) of patients completed the study. After switching to amisulpride, mean weight of patients significantly lowered compared to baseline (mean change: −1.2±2.0, p ＜0.0001). There was no significant change in extra-pyramidal side effect according to SAS (Table 4) . Table 5 shows the treatment-emergent SEs identified by the SAFTEE. The most frequently reported SEs after switching to amisulpride were insomnia (24.3%) and cognitive decline (18.9%). Dry mouth, headache, and constipation were relatively common SEs (for all 10.8%).
DISCUSSION
The present study investigated whether patients with schizophrenia who showed suboptimal efficacy or tolerability with their current antipsychotics benefit from a switch to amisulpride. More than half (56.8%) showed an improvement in CGI-CB score suggesting that switching to amisulpride resulted in clinical benefit. In line with previous studies, amisulpride was generally well tolerated with 24% discontinuation rate. 25) Notably, patient's mean body weight dropped by more than 1 kg while showing no worsening of EPS rated by SAS. Weight gain and its related metabolic syndrome are an important cause of long term morbidity and mortality of patient with schizophrenia, 30) hence amisulpride may be a viable alternative option especially in patients who are in overweight due to ongoing AAP treatment. 31) Interestingly, patient's SSS also showed a significant improvement after switching to amisulpride. The favorable SE outcome of amisulpride might have contributed to enhanced SSS because weight gain (43.2%) was the most common reported SE before switching. Nevertheless, the results suggested that switching to amisulpride has improved both objective and subjective scores of patients with schizophrenia.
The most common SEs by amisulpride were insomnia, cognitive decline, dry mouth, headache, and constipation. Above all, all SEs associated with amisulpride were mild to moderate in severity. High incidence of cognitive decline and dry mouth contradicted with previous findings because, having no muscarinic activities, amisulpride was known to have less anticholinergic SEs. 32) Memory decline and dry mouth rates were high, 24.3% and 10.8% respectively, even before patients switched to amisulpride. Thus, it is not possible to distinguish whether these SEs are caused from previous AAP or amisulpride.
Despite amisulpride has not yet been approved for the treatment of mood and anxiety disorders, its clinical potential for the treatment of major depressive disorder/dysthymia as well as anxiety symptoms including obsession has been extensively investigated and proved in a number of clinical studies. [33] [34] [35] [36] [37] Indeed selective modulation of dopaminergic system in the mesocorticolimbic area may account for improvement of depression and cognition. Hence its selective antagonism of dopamine D2-D3 receptors may partly explain about the antidepressive and anxiolytic effects, in fact animal studies have consistently support this notion; small to moderate doses (e.g., 50-100 mg/day) are known to be associated with the antidepressant effect, while moderate to medium doses (100-400 mg/day) for negative symptoms of schizophrenia. 38) However, these effects are still remains to be further explored.
Our study has several limitations. The study's naturalistic open-label design could be a shortcoming, we were therefore not able to rule-out bias related to unblendedrating. With no control group, it was not possible for us to compare effects of switching to amisulpride with that of non-switching or switching to other AAP. However, we must also mention that evidence not only from RCTs but also from naturalistic trials are needed to best reflect real clinical practice settings. All patients recruited were from teaching hospital, so the results may not be generalized to all clinical settings. Small sample size is another huge limitation.
In conclusion, the study suggests that a majority of patients switched to amisulpride from other AAP experienced more clinical benefit in terms of both efficacy and tolerability. Thus, amisulpride may be an alternative treatment option in patients with schizophrenia who are experiencing suboptimal efficacy or tolerability with ongoing antipsychotics. Adequately-powered and well-controlled RCTs are warranted to support the present findings in near future. This study was supported by Handok Pharmaceuticals (Prof . Pae). The funding source did not involve the study design, recruitment, study conduction, collection and interpretation of data, and manuscript drafting.
